Interestingly, Jones et al. recently reviewed results from a pediatric ALL xenograft platform, including one MLL-rearranged acute leukemia sample, and reported TOP1 inhibitor topotecan effectively inhibited ALL in seven out of eight PDX models [38]. Here, KMT2A is linked to acute leukemia.